Eastern Bank Sells 1,163 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Eastern Bank trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.9% in the fourth quarter, Holdings Channel reports. The firm owned 59,042 shares of the medical research company’s stock after selling 1,163 shares during the quarter. Eastern Bank’s holdings in IQVIA were worth $11,602,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Claro Advisors LLC bought a new stake in IQVIA in the 4th quarter valued at $281,000. Czech National Bank boosted its stake in IQVIA by 6.0% in the 4th quarter. Czech National Bank now owns 37,386 shares of the medical research company’s stock valued at $7,347,000 after purchasing an additional 2,107 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after purchasing an additional 56 shares during the period. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in IQVIA by 27.7% in the 4th quarter. GAMMA Investing LLC now owns 1,406 shares of the medical research company’s stock valued at $276,000 after acquiring an additional 305 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on IQV shares. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Truist Financial lowered their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Stock Performance

Shares of IQV traded up $1.21 on Monday, reaching $204.48. 822,684 shares of the company’s stock traded hands, compared to its average volume of 1,087,140. The stock’s 50 day simple moving average is $201.84 and its two-hundred day simple moving average is $221.77. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market cap of $37.11 billion, a PE ratio of 26.83, a PEG ratio of 2.05 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.